Development of Malaria Transmission-Blocking Vaccines: From Concept to Product

Advances in Parasitology

Volumn 89, Issue , 2015, Pages 109-152

  Wu, Yimin ^a,f   Sinden, Robert E ^b   Churcher, Thomas S ^c   Tsuboi, Takafumi ^d   Yusibov, Vidadi ^e  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UK   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d EHIME UNIVERSITY   (Japan)

^e Fraunhofer USA Inc   (United States)

^f PATH Malaria Vaccine Initiative   (United States)

Author keywords

Malaria; Transmission blocking; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; ALUMINUM SALT; BLOCKING ANTIBODY; CELL TRAVERSAL PROTEIN FOR OOKINETE AND SPOROZOITE; CIRCUMSPOROZOITE THROMBOSPONDIN RELATED ADHESIVE PROTEIN RELATED PROTEIN; EPIDERMAL GROWTH FACTOR; MALARIA TRANSMISSION BLOCKING VACCINE; MALARIA VACCINE; PERFORIN; PFS230 PROTEIN; PFS25 PROTEIN; POLYSACCHARIDE VACCINE; PROTEIN P25; PROTEIN P28; PVS25 PROTEIN; RECOMBINANT VACCINE; SECRETED OOKINETE ADHESIVE PROTEIN; SUBUNIT VACCINE; THROMBOSPONDIN; THROMBOSPONDIN RELATED ADHESIVE PROTEIN; UNCLASSIFIED DRUG; INSECT PROTEIN; PROTOZOAL PROTEIN; ADJUVANT;

ACTIVE IMMUNIZATION; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANOPHELES; ANOPHELES FARAUTI; ANOPHELES GAMBIAE; ANOPHELES STEPHENSI; ANOPHELES TESSELLATUS; ANTIBODY TITER; ARTICLE; BACULOVIRIDAE; BACULOVIRUS DUAL EXPRESSION SYSTEM; DNA LIBRARY; DNA POLYMORPHISM; DRUG EFFICACY; DRUG FORMULATION; ESCHERICHIA COLI; EXPRESSION VECTOR; GAMETE; GENE EXPRESSION SYSTEM; HERD IMMUNITY; HUMAN; IMMUNE EVASION; IMMUNITY; IMMUNOGENICITY; INNATE IMMUNITY; MALARIA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; PLASMODIUM GALLINACEUM; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; PLASMODIUM YOELII; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN MOTIF; PROTEIN TARGETING; SACCHAROMYCES CEREVISIAE; VIRUS PARTICLE; ANIMAL; CLINICAL TRIAL (TOPIC); ECONOMICS; GENETICS; IMMUNOLOGY; LIFE CYCLE STAGE; METABOLISM; MOSQUITO; PHYSIOLOGY; PLASMODIUM; STANDARDS; TRANSMISSION; DISEASE TRANSMISSION; ERYTHROCYTE; IMMUNIZATION;

ANIMALS; CLINICAL TRIALS AS TOPIC; CULICIDAE; HUMANS; INSECT PROTEINS; LIFE CYCLE STAGES; MALARIA; MALARIA VACCINES; PLASMODIUM; PROTOZOAN PROTEINS;

EID: 84938077984     PISSN: 0065308X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/bs.apar.2015.04.001     Document Type: Article

References (207)

1. Agnandji S.T., Lell B., Soulanoudjingar S.S., Fernandes J.F., Abossolo B.P., Conzelmann C. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N. Engl. J. Med. 2011, 365(20):1863-1875. RTS, S.C.T.P. 10.1056/NEJMoa1102287.
2. Alavi Y., Arai M., Mendoza J., Tufet-Bayona M., Sinha R., Fowler K., Sinden R.E. The dynamics of interactions between Plasmodium and the mosquito: a study of the infectivity of Plasmodium berghei and Plasmodium gallinaceum, and their transmission by Anopheles stephensi, Anopheles gambiae and Aedes aegypti. Int. J. Parasitol. 2003, 33(9):933-943.
3. Almeida A.P., Billingsley P.F. Induced immunity against the mosquito Anopheles stephensi (Diptera: Culicidae): effects of cell fraction antigens on survival, fecundity, and Plasmodium berghei (Eucoccidiida: Plasmodiidae) transmission. J. Med. Entomol. 2002, 39(1):207-214.
4. Alonso P.L., Brown G., Arevalo-Herrera M., Binka F., Chitnis C., Collins F., Tanner M. A research agenda to underpin malaria eradication. PLoS Med. 2011, 8(1):e1000406. 10.1371/journal.pmed.1000406.
5. Arevalo-Herrera M., Solarte Y., Rocha L., Alvarez D., Beier J.C., Herrera S. Characterization of Plasmodium vivax transmission-blocking activity in low to moderate malaria transmission settings of the Colombian Pacific coast. Am. J. Trop. Med. Hyg. 2011, 84(2 Suppl.):71-77. 10.4269/ajtmh.2011.10-0085.
6. Armistead J.S., Morlais I., Mathias D.K., Jardim J.G., Joy J., Fridman A., Dinglasan R.R. Antibodies to a single, conserved epitope in Anopheles APN1 inhibit universal transmission of Plasmodium falciparum and Plasmodium vivax malaria. Infect. Immun. 2014, 82(2):818-829. 10.1128/IAI.01222-13.
7. Aucouturier J., Dupuis L., Deville S., Ascarateil S., Ganne V. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev. Vaccines 2002, 1(1):111-118. 10.1586/14760584.1.1.111.
8. Barr P.J., Green K.M., Gibson H.L., Bathurst I.C., Quakyi I.A., Kaslow D.C. Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals. J. Exp. Med. 1991, 174(5):1203-1208.
9. Beier J.C., Copeland R.S., Mtalib R., Vaughan J.A. Ookinete rates in Afrotropical anopheline mosquitoes as a measure of human malaria infectiousness. Am. J. Trop. Med. Hyg. 1992, 47(1):41-46.
10. Bergmann-Leitner E.S., Mease R.M., De La Vega P., Savranskaya T., Polhemus M., Ockenhouse C., Angov E. Immunization with pre-erythrocytic antigen CelTOS from Plasmodium falciparum elicits cross-species protection against heterologous challenge with Plasmodium berghei. PLoS One 2010, 5(8):e12294. 10.1371/journal.pone.0012294.
11. Billingsley P.F., Medley G.F., Charlwood D., Sinden R.E. Relationship between prevalence and intensity of Plasmodium falciparum infection in natural populations of Anopheles mosquitoes. Am. J. Trop. Med. Hyg. 1994, 51(3):260-270.
12. Blagborough A.M., Churcher T.S., Upton L.M., Ghani A.C., Gething P.W., Sinden R.E. Transmission-blocking interventions eliminate malaria from laboratory populations. Nat. Commun. 2013, 4:1812. 10.1038/ncomms2840.
13. Blagborough A.M., Delves M.J., Ramakrishnan C., Lal K., Butcher G., Sinden R.E. Assessing transmission blockade in Plasmodium spp. Methods Mol. Biol. 2013, 923:577-600. 10.1007/978-1-62703-026-7_40.
14. Blagborough A.M., Sinden R.E. Plasmodium berghei HAP2 induces strong malaria transmission-blocking immunity in vivo and in vitro. Vaccine 2009, 27(38):5187-5194. 10.1016/j.vaccine.2009.06.069.
15. Blagborough A.M., Yoshida S., Sattabongkot J., Tsuboi T., Sinden R.E. Intranasal and intramuscular immunization with Baculovirus Dual Expression System-based Pvs25 vaccine substantially blocks Plasmodium vivax transmission. Vaccine 2010, 28(37):6014-6020. 10.1016/j.vaccine.2010.06.100.
16. Blanco A.R., Paez A., Gerold P., Dearsly A.L., Margos G., Schwarz R.T., Sinden R.E. The biosynthesis and post-translational modification of Pbs21 an ookinete-surface protein of Plasmodium berghei. Mol. Biochem. Parasitol. 1999, 98(2):163-173.
17. Bonnet S., Gouagna C., Safeukui I., Meunier J.Y., Boudin C. Comparison of artificial membrane feeding with direct skin feeding to estimate infectiousness of Plasmodium falciparum gametocyte carriers to mosquitoes. Trans. R. Soc. Trop. Med. Hyg. 2000, 94(1):103-106.
18. Bonnet S., Prevot G., Jacques J.C., Boudin C., Bourgouin C. Transcripts of the malaria vector Anopheles gambiae that are differentially regulated in the midgut upon exposure to invasive stages of Plasmodium falciparum. Cell. Microbiol. 2001, 3(7):449-458.
19. Bousema T., Dinglasan R.R., Morlais I., Gouagna L.C., van Warmerdam T., Awono-Ambene P.H., Churcher T.S. Mosquito feeding assays to determine the infectiousness of naturally infected Plasmodium falciparum gametocyte carriers. PLoS One 2012, 7(8):e42821. 10.1371/journal.pone.0042821.
20. Bousema T., Okell L., Shekalaghe S., Griffin J.T., Omar S., Sawa P., Drakeley C. Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malar. J. 2010, 9:136. 10.1186/1475-2875-9-136.
21. Bousema T., Roeffen W., Meijerink H., Mwerinde H., Mwakalinga S., van Gemert G.J., Drakeley C. The dynamics of naturally acquired immune responses to Plasmodium falciparum sexual stage antigens Pfs230 & Pfs48/45 in a low endemic area in Tanzania. PLoS One 2010, 5(11):e14114. 10.1371/journal.pone.0014114.
22. Brooks A., Nunes J.K., Garnett A., Biellik R., Leboulleux D., Birkett A.J., Loucq C. Aligning new interventions with developing country health systems: target product profiles, presentation, and clinical trial design. Glob. Public Health 2012, 7(9):931-945. 10.1080/17441692.2012.699088.
23. Buttery J.P., Lambert S.B., Grimwood K., Nissen M.D., Field E.J., Macartney K.K., Kirkwood C.D. Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia's national childhood vaccine schedule. Pediatr. Infect. Dis. J. 2011, 30(1 Suppl.):S25-S29. 10.1097/INF.0b013e3181fefdee.
24. Carter R., Chen D.H. Malaria transmission blocked by immunisation with gametes of the malaria parasite. Nature 1976, 263(5572):57-60.
25. Carter R., Coulson A., Bhatti S., Taylor B.J., Elliott J.F. Predicted disulfide-bonded structures for three uniquely related proteins of Plasmodium falciparum, Pfs230, Pfs48/45 and Pf12. Mol. Biochem. Parasitol. 1995, 71(2):203-210.
26. Carter R., Graves P.M., Keister D.B., Quakyi I.A. Properties of epitopes of Pfs 48/45, a target of transmission blocking monoclonal antibodies, on gametes of different isolates of Plasmodium falciparum. Parasite Immunol. 1990, 12(6):587-603.
27. Carter R., Kaushal D.C. Characterization of antigens on mosquito midgut stages of Plasmodium gallinaceum. III. Changes in zygote surface proteins during transformation to mature ookinete. Mol. Biochem. Parasitol. 1984, 13(2):235-241.
28. Chowdhury D.R., Angov E., Kariuki T., Kumar N. A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coli. PLoS One 2009, 4(7):e6352. 10.1371/journal.pone.0006352.
29. Churcher T.S., Blagborough A.M., Delves M., Ramakrishnan C., Kapulu M.C., Williams A.R., Sinden R.E. Measuring the blockade of malaria transmission-an analysis of the standard membrane feeding assay. Int. J. Parasitol. 2012, 42(11):1037-1044. 10.1016/j.ijpara.2012.09.002.
30. Churcher T.S., Dawes E.J., Sinden R.E., Christophides G.K., Koella J.C., Basanez M.G. Population biology of malaria within the mosquito: density-dependent processes and potential implications for transmission-blocking interventions. Malar. J. 2010, 9:311. 10.1186/1475-2875-9-311.
31. DeFrancesco L. Dynavax trial halted. Nat. Biotechnol. 2008, 26(5):484. 10.1038/nbt0508-484a.
32. Delrieu I., Leboulleux D., Ivinson K., Gessner B.D. Design of a phase III cluster randomized trial to assess the efficacy and safety of a malaria transmission blocking vaccine. Vaccine 2015, 33(13):1518-1526. Malaria Transmission Blocking Vaccine Technical Consultation, G. 10.1016/j.vaccine.2015.01.050.
33. Dessens J.T., Beetsma A.L., Dimopoulos G., Wengelnik K., Crisanti A., Kafatos F.C., Sinden R.E. CTRP is essential for mosquito infection by malaria ookinetes. EMBO J. 1999, 18(22):6221-6227. 10.1093/emboj/18.22.6221.
34. Dessens J.T., Mendoza J., Claudianos C., Vinetz J.M., Khater E., Hassard S., Sinden R.E. Knockout of the rodent malaria parasite chitinase pbCHT1 reduces infectivity to mosquitoes. Infect. Immun. 2001, 69(6):4041-4047. 10.1128/IAI.69.6.4041-4047.2001.
35. Dessens J.T., Siden-Kiamos I., Mendoza J., Mahairaki V., Khater E., Vlachou D., Sinden R.E. SOAP, a novel malaria ookinete protein involved in mosquito midgut invasion and oocyst development. Mol. Microbiol. 2003, 49(2):319-329.
36. Dinglasan R.R., Armistead J.S., Nyland J.F., Jiang X., Mao H.Q. Single-dose microparticle delivery of a malaria transmission-blocking vaccine elicits a long-lasting functional antibody response. Curr. Mol. Med. 2013, 13(4):479-487.
37. Dinglasan R.R., Kalume D.E., Kanzok S.M., Ghosh A.K., Muratova O., Pandey A., Jacobs-Lorena M. Disruption of Plasmodium falciparum development by antibodies against a conserved mosquito midgut antigen. Proc. Natl. Acad. Sci. U.S.A. 2007, 104(33):13461-13466. 10.1073/pnas.0702239104.
38. Doi M., Tanabe K., Tachibana S., Hamai M., Tachibana M., Mita T., Tsuboi T. Worldwide sequence conservation of transmission-blocking vaccine candidate Pvs230 in Plasmodium vivax. Vaccine 2011, 29(26):4308-4315. 10.1016/j.vaccine.2011.04.028.
39. Duffy P.E., Kaslow D.C. A novel malaria protein, Pfs28, and Pfs25 are genetically linked and synergistic as falciparum malaria transmission-blocking vaccines. Infect. Immun. 1997, 65(3):1109-1113.
40. van Dijk M.R., Janse C.J., Thompson J., Waters A.P., Braks J.A., Dodemont H.J., Eling W. A central role for P48/45 in malaria parasite male gamete fertility. Cell 2001, 104(1):153-164.
41. Da D.F., Dixit S., Sattabonkot J., Mu J., Abate L., Ramineni B., Wu Y. Anti-Pfs25 human plasma reduces transmission of Plasmodium falciparum isolates that have diverse genetic backgrounds. Infect. Immun. 2013, 81(6):1984-1989. 10.1128/IAI.00016-13.
42. Eksi S., Czesny B., van Gemert G.J., Sauerwein R.W., Eling W., Williamson K.C. Malaria transmission-blocking antigen, Pfs230, mediates human red blood cell binding to exflagellating male parasites and oocyst production. Mol. Microbiol. 2006, 61(4):991-998. 10.1111/j.1365-2958.2006.05284.x.
43. Eksi S., Stump A., Fanning S.L., Shenouda M.I., Fujioka H., Williamson K.C. Targeting and sequestration of truncated Pfs230 in an intraerythrocytic compartment during Plasmodium falciparum gametocytogenesis. Mol. Microbiol. 2002, 44(6):1507-1516.
44. Escalante A.A., Grebert H.M., Chaiyaroj S.C., Riggione F., Biswas S., Nahlen B.L., Lal A.A. Polymorphism in the gene encoding the Pfs48/45 antigen of Plasmodium falciparum. XI. Asembo Bay Cohort Project. Mol. Biochem. Parasitol. 2002, 119(1):17-22.
45. Farrance C.E., Chichester J.A., Musiychuk K., Shamloul M., Rhee A., Manceva S.D., Yusibov V. Antibodies to plant-produced Plasmodium falciparum sexual stage protein Pfs25 exhibit transmission blocking activity. Hum. Vaccines 2011, (7 Suppl.):191-198.
46. Farrance C.E., Rhee A., Jones R.M., Musiychuk K., Shamloul M., Sharma S., Yusibov V. A plant-produced Pfs230 vaccine candidate blocks transmission of Plasmodium falciparum. Clin. Vaccine Immunol. 2011, 18(8):1351-1357. 10.1128/CVI.05105-11.
47. Fernandes F., Teixeira A.P., Carinhas N., Carrondo M.J., Alves P.M. Insect cells as a production platform of complex virus-like particles. Expert Rev. Vaccines 2013, 12(2):225-236. 10.1586/erv.12.153.
48. Gastanaduy P.A., Curns A.T., Parashar U.D., Lopman B.A. Gastroenteritis hospitalizations in older children and adults in the United States before and after implementation of infant rotavirus vaccination. JAMA 2013, 310(8):851-853. 10.1001/jama.2013.170800.
49. Gerloff D.L., Creasey A., Maslau S., Carter R. Structural models for the protein family characterized by gamete surface protein Pfs230 of Plasmodium falciparum. Proc. Natl. Acad. Sci. U.S.A. 2005, 102(38):13598-13603. 10.1073/pnas.0502378102.
50. Gholizadeh S., Basseri H.R., Zakeri S., Ladoni H., Djadid N.D. Cloning, expression and transmission-blocking activity of anti-PvWARP, malaria vaccine candidate, in Anopheles stephensi mysorensis. Malar. J. 2010, 9:158. 10.1186/1475-2875-9-158.
51. Ghosh A.K., Devenport M., Jethwaney D., Kalume D.E., Pandey A., Anderson V.E., Jacobs-Lorena M. Malaria parasite invasion of the mosquito salivary gland requires interaction between the Plasmodium TRAP and the Anopheles saglin proteins. PLoS Pathog. 2009, 5(1):e1000265. 10.1371/journal.ppat.1000265.
52. Gonzalez-Ceron L., Alvarado-Delgado A., Martinez-Barnetche J., Rodriguez M.H., Ovilla-Munoz M., Perez F., Villarreal-Trevino C. Sequence variation of ookinete surface proteins Pvs25 and Pvs28 of Plasmodium vivax isolates from Southern Mexico and their association to local anophelines infectivity. Infect. Genet. Evol. 2010, 10(5):645-654. 10.1016/j.meegid.2010.03.014.
53. Goodman A.L., Blagborough A.M., Biswas S., Wu Y., Hill A.V., Sinden R.E., Draper S.J. A viral vectored prime-boost immunization regime targeting the malaria Pfs25 antigen induces transmission-blocking activity. PLoS One 2011, 6(12):e29428. 10.1371/journal.pone.0029428.
54. Gouagna L.C., Yao F., Yameogo B., Dabire R.K., Ouedraogo J.B. Comparison of field-based xenodiagnosis and direct membrane feeding assays for evaluating host infectiousness to malaria vector Anopheles gambiae. Acta Trop. 2013, 130C:131-139. 10.1016/j.actatropica.2013.10.022.
55. Gozar M.M., Muratova O., Keister D.B., Kensil C.R., Price V.L., Kaslow D.C. Plasmodium falciparum: immunogenicity of alum-adsorbed clinical-grade TBV25-28, a yeast-secreted malaria transmission-blocking vaccine candidate. Exp. Parasitol. 2001, 97(2):61-69. 10.1006/expr.2000.4580.
56. Graves P.M., Burkot T.R., Carter R., Cattani J.A., Lagog M., Parker J., Alpers M.P. Measurement of malarial infectivity of human populations to mosquitoes in the Madang area, Papua, New Guinea. Parasitology 1988, 96(Pt 2):251-263.
57. Graves P.M., Carter R., Burkot T.R., Quakyi I.A., Kumar N. Antibodies to Plasmodium falciparum gamete surface antigens in Papua New Guinea sera. Parasite Immunol. 1988, 10(2):209-218.
58. Gregory A.E., Titball R., Williamson D. Vaccine delivery using nanoparticles. Front. Cell. Infect. Microbiol. 2013, 3:13. 10.3389/fcimb.2013.00013.
59. Grotendorst C.A., Carter R. Complement effects of the infectivity of Plasmodium gallinaceum to Aedes aegypti mosquitoes. II. Changes in sensitivity to complement-like factors during zygote development. J. Parasitol. 1987, 73(5):980-984.
60. Grotendorst C.A., Kumar N., Carter R., Kaushal D.C. A surface protein expressed during the transformation of zygotes of Plasmodium gallinaceum is a target of transmission-blocking antibodies. Infect. Immun. 1984, 45(3):775-777.
61. Gwadz R.W. Successful immunization against the sexual stages of Plasmodium gallinaceum. Science 1976, 193(4258):1150-1151.
62. Hafalla J.C., Santiago M.L., Pasay M.C., Ramirez B.L., Gozar M.M., Saul A., Kaslow D.C. Minimal variation in the Pfs28 ookinete antigen from Philippine field isolates of Plasmodium falciparum. Mol. Biochem. Parasitol. 1997, 87(1):97-99.
63. Healer J., McGuinness D., Hopcroft P., Haley S., Carter R., Riley E. Complement-mediated lysis of Plasmodium falciparum gametes by malaria-immune human sera is associated with antibodies to the gamete surface antigen Pfs230. Infect. Immun. 1997, 65(8):3017-3023.
64. Herrera S., Fernandez O.L., Vera O., Cardenas W., Ramirez O., Palacios R., Arevalo-Herrera M. Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51. Am. J. Trop. Med. Hyg. 2011, 84(2 Suppl.):12-20. 10.4269/ajtmh.2011.09-0516.
65. Hill A.V., Reyes-Sandoval A., O'Hara G., Ewer K., Lawrie A., Goodman A., Draper S.J. Prime-boost vectored malaria vaccines: progress and prospects. Hum. Vaccines 2010, 6(1):78-83.
66. Hisaeda H., Stowers A.W., Tsuboi T., Collins W.E., Sattabongkot J.S., Suwanabun N., Kaslow D.C. Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes. Infect. Immun. 2000, 68(12):6618-6623.
67. Hu J., Chen Z., Gu J., Wan M., Shen Q., Kieny M.P., Pan W. Safety and immunogenicity of a malaria vaccine, Plasmodium falciparum AMA-1/MSP-1 chimeric protein formulated in montanide ISA 720 in healthy adults. PLoS One 2008, 3(4):e1952. 10.1371/journal.pone.0001952.
68. Huber M., Cabib E., Miller L.H. Malaria parasite chitinase and penetration of the mosquito peritrophic membrane. Proc. Natl. Acad. Sci. U.S.A. 1991, 88(7):2807-2810.
69. Huff C.G., Marchbank D.F., Shiroishi T. Changes in infectiousness of malarial gametocytes. II. Analysis of the possible causative factors. Exp. Parasitol. 1958, 7(4):399-417.
70. Jones R.M., Chichester J.A., Mett V., Jaje J., Tottey S., Manceva S., Yusibov V. A plant-produced Pfs25 VLP malaria vaccine candidate induces persistent transmission blocking antibodies against Plasmodium falciparum in immunized mice. PLoS One 2013, 8(11):e79538. 10.1371/journal.pone.0079538.
71. Kadota K., Ishino T., Matsuyama T., Chinzei Y., Yuda M. Essential role of membrane-attack protein in malarial transmission to mosquito host. Proc. Natl. Acad. Sci. U.S.A. 2004, 101(46):16310-16315. 10.1073/pnas.0406187101.
72. Kaiser K., Camargo N., Coppens I., Morrisey J.M., Vaidya A.B., Kappe S.H. A member of a conserved Plasmodium protein family with membrane-attack complex/perforin (MACPF)-like domains localizes to the micronemes of sporozoites. Mol. Biochem. Parasitol. 2004, 133(1):15-26.
73. Kariu T., Ishino T., Yano K., Chinzei Y., Yuda M. CelTOS, a novel malarial protein that mediates transmission to mosquito and vertebrate hosts. Mol. Microbiol. 2006, 59(5):1369-1379. 10.1111/j.1365-2958.2005.05024.x.
74. Kaslow D.C. Transmission-blocking vaccines. Chem. Immunol. 2002, 80:287-307.
75. Kaslow D.C., Bathurst I.C., Isaacs S.N., Keister D.B., Moss B., Barr P.J. Induction of Plasmodium falciparum transmission-blocking antibodies by recombinant Pfs25. Mem. Inst. Oswaldo Cruz 1992, 87(Suppl. 3):175-177.
76. Kaslow D.C., Bathurst I.C., Lensen T., Ponnudurai T., Barr P.J., Keister D.B. Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum. Infect. Immun. 1994, 62(12):5576-5580.
77. Kaslow D.C., Quakyi I.A., Keister D.B. Minimal variation in a vaccine candidate from the sexual stage of Plasmodium falciparum. Mol. Biochem. Parasitol. 1989, 32(1):101-103.
78. Kaslow D.C., Quakyi I.A., Syin C., Raum M.G., Keister D.B., Coligan J.E., Miller L.H. A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. Nature 1988, 333(6168):74-76. 10.1038/333074a0.
79. Kaslow D.C., Shiloach J. Production, purification and immunogenicity of a malaria transmission-blocking vaccine candidate: TBV25H expressed in yeast and purified using nickel-NTA agarose. Biotechnol. N. Y. 1994, 12(5):494-499.
80. Kaushal D.C., Carter R., Rener J., Grotendorst C.A., Miller L.H., Howard R.J. Monoclonal antibodies against surface determinants on gametes of Plasmodium gallinaceum block transmission of malaria parasites to mosquitoes. J. Immunol. 1983, 131(5):2557-2562.
81. Kelly D.F., Moxon E.R., Pollard A.J. Haemophilus influenzae type b conjugate vaccines. Immunology 2004, 113(2):163-174. 10.1111/j.1365-2567.2004.01971.x.
82. Kim T.S., Kim H.H., Kim J.Y., Kong Y., Na B.K., Lin K., Lee H.W. Comparison of the antibody responses to Plasmodium vivax and Plasmodium falciparum antigens in residents of Mandalay, Myanmar. Malar. J. 2011, 10:228. 10.1186/1475-2875-10-228.
83. Kim T.S., Kim H.H., Moon S.U., Lee S.S., Shin E.H., Oh C.M., Lee H.W. The role of Pvs28 in sporozoite development in Anopheles sinensis and its longevity in BALB/c mice. Exp. Parasitol. 2011, 127(2):346-350. 10.1016/j.exppara.2010.08.015.
84. Kocken C.H., Jansen J., Kaan A.M., Beckers P.J., Ponnudurai T., Kaslow D.C., Schoenmakers J.G. Cloning and expression of the gene coding for the transmission blocking target antigen Pfs48/45 of Plasmodium falciparum. Mol. Biochem. Parasitol. 1993, 61(1):59-68.
85. Kubler-Kielb J., Majadly F., Biesova Z., Mocca C.P., Guo C., Nussenzweig R., Schneerson R. A bicomponent Plasmodium falciparum investigational vaccine composed of protein-peptide conjugates. Proc. Natl. Acad. Sci. U.S.A. 2010, 107(3):1172-1177. 10.1073/pnas.0913374107.
86. Kubler-Kielb J., Majadly F., Wu Y., Narum D.L., Guo C., Miller L.H., Schneerson R. Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25. Proc. Natl. Acad. Sci. U.S.A. 2007, 104(1):293-298. 10.1073/pnas.0609885104.
87. Kumar N. Phase separation in Triton X-114 of antigens of transmission blocking immunity in Plasmodium gallinaceum. Mol. Biochem. Parasitol. 1985, 17(3):343-358.
88. Kumar N., Carter R. Biosynthesis of the target antigens of antibodies blocking transmission of Plasmodium falciparum. Mol. Biochem. Parasitol. 1984, 13(3):333-342.
89. Kumar N., Carter R. Biosynthesis of two stage-specific membrane proteins during transformation of Plasmodium gallinaceum zygotes into ookinetes. Mol. Biochem. Parasitol. 1985, 14(2):127-139.
90. Kumar R., Angov E., Kumar N. Potent malaria transmission-blocking antibody responses elicited by Plasmodium falciparum Pfs25 expressed in Escherichia coli after Successful protein refolding. Infect. Immun. 2014, 82(4):1453-1459. 10.1128/IAI.01438-13.
91. van der Kolk M., De Vlas S.J., Saul A., van de Vegte-Bolmer M., Eling W.M., Sauerwein R.W. Evaluation of the standard membrane feeding assay (SMFA) for the determination of malaria transmission-reducing activity using empirical data. Parasitology 2005, 130(Pt 1):13-22.
92. Lal A.A., Patterson P.S., Sacci J.B., Vaughan J.A., Paul C., Collins W.E., Azad A.F. Anti-mosquito midgut antibodies block development of Plasmodium falciparum and Plasmodium vivax in multiple species of Anopheles mosquitoes and reduce vector fecundity and survivorship. Proc. Natl. Acad. Sci. U.S.A. 2001, 98(9):5228-5233. 10.1073/pnas.091447398.
93. Lavazec C., Bonnet S., Thiery I., Boisson B., Bourgouin C. cpbAg1 encodes an active carboxypeptidase B expressed in the midgut of Anopheles gambiae. Insect Mol. Biol. 2005, 14(2):163-174. 10.1111/j.1365-2583.2004.00541.x.
94. Lavazec C., Boudin C., Lacroix R., Bonnet S., Diop A., Thiberge S., Bourgouin C. Carboxypeptidases B of Anopheles gambiae as targets for a Plasmodium falciparum transmission-blocking vaccine. Infect. Immun. 2007, 75(4):1635-1642. 10.1128/IAI.00864-06.
95. Lawrence G.W., Saul A., Giddy A.J., Kemp R., Pye D. Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720. Vaccine 1997, 15(2):176-178.
96. Lensen A.H., Van Gemert G.J., Bolmer M.G., Meis J.F., Kaslow D., Meuwissen J.H., Ponnudurai T. Transmission blocking antibody of the Plasmodium falciparum zygote/ookinete surface protein Pfs25 also influences sporozoite development. Parasite Immunol. 1992, 14(5):471-479.
97. Li F., Patra K.P., Vinetz J.M. An anti-chitinase malaria transmission-blocking single-chain antibody as an effector molecule for creating a Plasmodium falciparum-refractory mosquito. J. Infect. Dis. 2005, 192(5):878-887. 10.1086/432552.
98. Li F., Templeton T.J., Popov V., Comer J.E., Tsuboi T., Torii M., Vinetz J.M. Plasmodium ookinete-secreted proteins secreted through a common micronemal pathway are targets of blocking malaria transmission. J. Biol. Chem. 2004, 279(25):26635-26644. 10.1074/jbc.M401385200.
99. Lin F.Y., Ho V.A., Khiem H.B., Trach D.D., Bay P.V., Thanh T.C., Szu S.C. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N. Engl. J. Med. 2001, 344(17):1263-1269. 10.1056/NEJM200104263441701.
100. Liu Y., Tewari R., Ning J., Blagborough A.M., Garbom S., Pei J., Billker O. The conserved plant sterility gene HAP2 functions after attachment of fusogenic membranes in Chlamydomonas and Plasmodium gametes. Genes Dev. 2008, 22(8):1051-1068. 10.1101/gad.1656508.
101. Malkin E.M., Durbin A.P., Diemert D.J., Sattabongkot J., Wu Y., Miura K., Saul A. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 2005, 23(24):3131-3138. 10.1016/j.vaccine.2004.12.019.
102. Margos G., Navarette S., Butcher G., Davies A., Willers C., Sinden R.E., Lachmann P.J. Interaction between host complement and mosquito-midgut-stage Plasmodium berghei. Infect. Immun. 2001, 69(8):5064-5071. 10.1128/IAI.69.8.5064-5071.2001.
103. Mathias D.K., Plieskatt J.L., Armistead J.S., Bethony J.M., Abdul-Majid K.B., McMillan A., Dinglasan R.R. Expression, immunogenicity, histopathology, and potency of a mosquito-based malaria transmission-blocking recombinant vaccine. Infect. Immun. 2012, 80(4):1606-1614. 10.1128/IAI.06212-11.
104. McCarthy J.S., Marjason J., Elliott S., Fahey P., Bang G., Malkin E., Anders R.F. A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide(R) ISA 720. PLoS One 2011, 6(9):e24413. 10.1371/journal.pone.0024413.
105. Medley G.F., Sinden R.E., Fleck S., Billingsley P.F., Tirawanchai N., Rodriguez M.H. Heterogeneity in patterns of malarial oocyst infections in the mosquito vector. Parasitology 1993, 106(Pt 5):441-449.
106. Mendis K.N., Munesinghe Y.D., de Silva Y.N., Keragalla I., Carter R. Malaria transmission-blocking immunity induced by natural infections of Plasmodium vivax in humans. Infect. Immun. 1987, 55(2):369-372.
107. Milek R.L., DeVries A.A., Roeffen W.F., Stunnenberg H., Rottier P.J., Konings R.N. Plasmodium falciparum: heterologous synthesis of the transmission-blocking vaccine candidate Pfs48/45 in recombinant vaccinia virus-infected cells. Exp. Parasitol. 1998, 90(2):165-174. 10.1006/expr.1998.4315.
108. Milek R.L., Roeffen W.F., Kocken C.H., Jansen J., Kaan A.M., Eling W.M., Konings R.N. Immunological properties of recombinant proteins of the transmission blocking vaccine candidate, Pfs48/45, of the human malaria parasite Plasmodium falciparum produced in Escherichia coli. Parasite Immunol. 1998, 20(8):377-385.
109. Milek R.L., Stunnenberg H.G., Konings R.N. Assembly and expression of a synthetic gene encoding the antigen Pfs48/45 of the human malaria parasite Plasmodium falciparum in yeast. Vaccine 2000, 18(14):1402-1411.
110. Miles A.P., Zhang Y., Saul A., Stowers A.W. Large-scale purification and characterization of malaria vaccine candidate antigen Pvs25H for use in clinical trials. Protein Expr. Purif. 2002, 25(1):87-96. 10.1006/prep.2001.1613.
111. Miura K., Deng B., Tullo G., Diouf A., Moretz S.E., Locke E., Long C.A. Qualification of standard membrane-feeding assay with Plasmodium falciparum malaria and potential improvements for future assays. PLoS One 2013, 8(3):e57909. 10.1371/journal.pone.0057909.
112. Miura K., Keister D.B., Muratova O.V., Sattabongkot J., Long C.A., Saul A. Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer. Malar. J. 2007, 6:107. 10.1186/1475-2875-6-107.
113. Miura K., Takashima E., Deng B., Tullo G., Diouf A., Moretz S.E., Tsuboi T. Functional comparison of Plasmodium falciparum transmission-blocking vaccine candidates by the standard membrane-feeding assay. Infect. Immun. 2013, 81(12):4377-4382. 10.1128/IAI.01056-13.
114. Miyata T., Harakuni T., Tsuboi T., Sattabongkot J., Ikehara A., Tachibana M., Arakawa T. Tricomponent immunopotentiating system as a novel molecular design strategy for malaria vaccine development. Infect. Immun. 2011, 79(10):4260-4275. 10.1128/IAI.05214-11.
115. Miyata T., Harakuni T., Tsuboi T., Sattabongkot J., Kohama H., Tachibana M., Arakawa T. Plasmodium vivax ookinete surface protein Pvs25 linked to cholera toxin B subunit induces potent transmission-blocking immunity by intranasal as well as subcutaneous immunization. Infect. Immun. 2010, 78(9):3773-3782. 10.1128/IAI.00306-10.
116. Mizutani M., Iyori M., Blagborough A.M., Fukumoto S., Funatsu T., Sinden R.E., Yoshida S. Baculovirus-vectored multistage Plasmodium vivax vaccine induces both protective and transmission-blocking immunities against transgenic rodent malaria parasites. Infect. Immun. 2014, 82(10):4348-4357. 10.1128/IAI.02040-14.
117. Mlambo G., Kumar N., Yoshida S. Functional immunogenicity of baculovirus expressing Pfs25, a human malaria transmission-blocking vaccine candidate antigen. Vaccine 2010, 28(43):7025-7029. 10.1016/j.vaccine.2010.08.022.
118. Molina-Cruz A., Barillas-Mury C. The remarkable journey of adaptation of the Plasmodium falciparum malaria parasite to New World anopheline mosquitoes. Mem. Inst. Oswaldo Cruz 2014, 0:17-20.
119. Moorthy V.S., Newman R.D., Okwo-Bele J.M. Malaria vaccine technology roadmap. Lancet 2013, 382(9906):1700-1701. 10.1016/S0140-6736(13)62238-2.
120. Mori T., Hirai M., Kuroiwa T., Miyagishima S.Y. The functional domain of GCS1-based gamete fusion resides in the amino terminus in plant and parasite species. PLoS One 2010, 5(12):e15957. 10.1371/journal.pone.0015957.
121. Niederwieser I., Felger I., Beck H.P. Limited polymorphism in Plasmodium falciparum sexual-stage antigens. Am. J. Trop. Med. Hyg. 2001, 64(1-2):9-11.
122. Nolz J.C., Harty J.T. Strategies and implications for prime-boost vaccination to generate memory CD8 T cells. Adv. Exp. Med. Biol. 2011, 780:69-83. 10.1007/978-1-4419-5632-3_7.
123. Okulate M.A., Kalume D.E., Reddy R., Kristiansen T., Bhattacharyya M., Chaerkady R., Kumar N. Identification and molecular characterization of a novel protein Saglin as a target of monoclonal antibodies affecting salivary gland infectivity of Plasmodium sporozoites. Insect Mol. Biol. 2007, 16(6):711-722. 10.1111/j.1365-2583.2007.00765.x.
124. Oliveira G.A., Wetzel K., Calvo-Calle J.M., Nussenzweig R., Schmidt A., Birkett A., Nardin E.H. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial. Infect. Immun. 2005, 73(6):3587-3597. 10.1128/IAI.73.6.3587-3597.2005.
125. Olotu A., Fegan G., Wambua J., Nyangweso G., Awuondo K.O., Leach A., Bejon P. Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure. N. Engl. J. Med. 2013, 368(12):1111-1120. 10.1056/NEJMoa1207564.
126. Ong C.S., Zhang K.Y., Eida S.J., Graves P.M., Dow C., Looker M., Targett G.A. The primary antibody response of malaria patients to Plasmodium falciparum sexual stage antigens which are potential transmission blocking vaccine candidates. Parasite Immunol. 1990, 12(5):447-456.
127. Ouedraogo A.L., Roeffen W., Luty A.J., de Vlas S.J., Nebie I., Ilboudo-Sanogo E., Sauerwein R. Naturally acquired immune responses to Plasmodium falciparum sexual stage antigens Pfs48/45 and Pfs230 in an area of seasonal transmission. Infect. Immun. 2011, 79(12):4957-4964. 10.1128/IAI.05288-11.
128. Outchkourov N.S., Roeffen W., Kaan A., Jansen J., Luty A., Schuiffel D., Stunnenberg H.G. Correctly folded Pfs48/45 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in mice. Proc. Natl. Acad. Sci. U.S.A. 2008, 105(11):4301-4305. 10.1073/pnas.0800459105.
129. Passwell J.H., Ashkenazi S., Harlev E., Miron D., Ramon R., Farzam N. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children. Pediatr. Infect. Dis. J. 2003, 22(8):701-706. Israel Shigella Study, G. 10.1097/01.inf.0000078156.03697.a5.
130. Passwell J.H., Ashkenzi S., Banet-Levi Y., Ramon-Saraf R., Farzam N., Lerner-Geva L. Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children. Vaccine 2010, 28(10):2231-2235. Israeli Shigella Study, G. 10.1016/j.vaccine.2009.12.050.
131. Pichichero M.E. Protein carriers of conjugate vaccines: characteristics, development and clinical trials. Hum. Vaccines Immunother. 2013, 9(12).
132. Ponsa N., Sattabongkot J., Kittayapong P., Eikarat N., Coleman R.E. Transmission-blocking activity of tafenoquine (WR-238605) and artelinic acid against naturally circulating strains of Plasmodium vivax in Thailand. Am. J. Trop. Med. Hyg. 2003, 69(5):542-547.
133. Premawansa S., Gamage-Mendis A., Perera L., Begarnie S., Mendis K., Carter R. Plasmodium falciparum malaria transmission-blocking immunity under conditions of low endemicity as in Sri Lanka. Parasite Immunol. 1994, 16(1):35-42.
134. Qian F., Aebig J.A., Reiter K., Barnafo E., Zhang Y., Shimp R.L., Wu Y. Enhanced antibody responses to Plasmodium falciparum Pfs28 induced in mice by conjugation to ExoProtein A of Pseudomonas aeruginosa with an improved procedure. Microbes Infect. 2009, 11(3):408-412. 10.1016/j.micinf.2008.12.009.
135. Qian F., Rausch K.M., Muratova O., Zhou H., Song G., Diouf A., Mullen G.E. Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders. Vaccine 2008, 26(20):2521-2527. 10.1016/j.vaccine.2008.03.005.
136. Qian F., Wu Y., Muratova O., Zhou H., Dobrescu G., Duggan P., Mullen G.E. Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates. Vaccine 2007, 25(20):3923-3933. 10.1016/j.vaccine.2007.02.073.
137. Quakyi I.A., Carter R., Rener J., Kumar N., Good M.F., Miller L.H. The 230-kDa gamete surface protein of Plasmodium falciparum is also a target for transmission-blocking antibodies. J. Immunol. 1987, 139(12):4213-4217.
138. Ramakrishnan C., Dessens J.T., Armson R., Pinto S.B., Talman A.M., Blagborough A.M., Sinden R.E. Vital functions of the malarial ookinete protein, CTRP, reside in the A domains. Int. J. Parasitol. 2011, 41(10):1029-1039. 10.1016/j.ijpara.2011.05.007.
139. Ramasamy M.S., Ramasamy R. Effect of anti-mosquito antibodies on the infectivity of the rodent malaria parasite Plasmodium berghei to Anopheles farauti. Med. Vet. Entomol. 1990, 4(2):161-166.
140. Ramjanee S., Robertson J.S., Franke-Fayard B., Sinha R., Waters A.P., Janse C.J., Sinden R.E. The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials. Vaccine 2007, 25(5):886-894. 10.1016/j.vaccine.2006.09.035.
141. Rashid H., Khandaker G., Booy R. Vaccination and herd immunity: what more do we know?. Curr. Opin. Infect. Dis. 2012, 25(3):243-249. 10.1097/QCO.0b013e328352f727.
142. Read D., Lensen A.H., Begarnie S., Haley S., Raza A., Carter R. Transmission-blocking antibodies against multiple, non-variant target epitopes of the Plasmodium falciparum gamete surface antigen Pfs230 are all complement-fixing. Parasite Immunol. 1994, 16(10):511-519.
143. Rener J., Graves P.M., Carter R., Williams J.L., Burkot T.R. Target antigens of transmission-blocking immunity on gametes of Plasmodium falciparum. J. Exp. Med. 1983, 158(3):976-981.
144. Richards J.S., MacDonald N.J., Eisen D.P. Limited polymorphism in Plasmodium falciparum ookinete surface antigen, von Willebrand factor A domain-related protein from clinical isolates. Malar. J. 2006, 5:55. 10.1186/1475-2875-5-55.
145. Riley E.M., Bennett S., Jepson A., Hassan-King M., Whittle H., Olerup O., Carter R. Human antibody responses to Pfs 230, a sexual stage-specific surface antigen of Plasmodium falciparum: non-responsiveness is a stable phenotype but does not appear to be genetically regulated. Parasite Immunol. 1994, 16(2):55-62.
146. Roberts L., Enserink M. Malaria. Did they really say. . . eradication?. Science 2007, 318(5856):1544-1545. 10.1126/science.318.5856.1544.
147. Roeffen W., Geeraedts F., Eling W., Beckers P., Wizel B., Kumar N., Sauerwein R. Transmission blockade of Plasmodium falciparum malaria by anti-Pfs230-specific antibodies is isotype dependent. Infect. Immun. 1995, 63(2):467-471.
148. Roeffen W., Teelen K., van As J., vd Vegte-Bolmer M., Eling W., Sauerwein R. Plasmodium falciparum: production and characterization of rat monoclonal antibodies specific for the sexual-stage Pfs48/45 antigen. Exp. Parasitol. 2001, 97(1):45-49. 10.1006/expr.2000.4586.
149. Rypniewski W.R., Perrakis A., Vorgias C.E., Wilson K.S. Evolutionary divergence and conservation of trypsin. Protein Eng. 1994, 7(1):57-64.
150. Sattabongkot J., Tsuboi T., Hisaeda H., Tachibana M., Suwanabun N., Rungruang T., Torii M. Blocking of transmission to mosquitoes by antibody to Plasmodium vivax malaria vaccine candidates Pvs25 and Pvs28 despite antigenic polymorphism in field isolates. Am. J. Trop. Med. Hyg. 2003, 69(5):536-541.
151. Saul A. Efficacy model for mosquito stage transmission blocking vaccines for malaria. Parasitology 2008, 135(13):1497-1506. 10.1017/S0031182008000280.
152. Saul A., Fay M.P. Human immunity and the design of multi-component, single target vaccines. PLoS One 2007, 2(9):e850. 10.1371/journal.pone.0000850.
153. Saul A., Hensmann M., Sattabongkot J., Collins W.E., Barnwell J.W., Langermans J.A., Thomas A.W. Immunogenicity in rhesus of the Plasmodium vivax mosquito stage antigen Pvs25H with Alhydrogel and Montanide ISA 720. Parasite Immunol. 2007, 29(10):525-533. 10.1111/j.1365-3024.2007.00971.x.
154. Saul A., Lawrence G., Allworth A., Elliott S., Anderson K., Rzepczyk C., Anders R.F. A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant. Vaccine 2005, 23(23):3076-3083. 10.1016/j.vaccine.2004.09.040.
155. Saul A., Lawrence G., Smillie A., Rzepczyk C.M., Reed C., Taylor D., Sturchler D. Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant. Vaccine 1999, 17(23-24):3145-3159.
156. Saxena A.K., Singh K., Su H.P., Klein M.M., Stowers A.W., Saul A.J., Garboczi D.N. The essential mosquito-stage P25 and P28 proteins from Plasmodium form tile-like triangular prisms. Nat. Struct. Mol. Biol. 2006, 13(1):90-91. 10.1038/nsmb1024.
157. Schwartz L., Brown G.V., Genton B., Moorthy V.S. A review of malaria vaccine clinical projects based on the WHO rainbow table. Malar. J. 2012, 11:11. 10.1186/1475-2875-11-11.
158. Shahabuddin M., Kaidoh T., Aikawa M., Kaslow D.C. Plasmodium gallinaceum: mosquito peritrophic matrix and the parasite-vector compatibility. Exp. Parasitol. 1995, 81(3):386-393. 10.1006/expr.1995.1129.
159. Shahabuddin M., Lemos F.J., Kaslow D.C., Jacobs-Lorena M. Antibody-mediated inhibition of Aedes aegypti midgut trypsins blocks sporogonic development of Plasmodium gallinaceum. Infect. Immun. 1996, 64(3):739-743.
160. Sharma B. Structure and mechanism of a transmission blocking vaccine candidate protein Pfs25 from P. falciparum: a molecular modeling and docking study. In Silico Biol. 2008, 8(3-4):193-206.
161. Sharma B., Jaiswal M.K., Saxena A.K. EGF domain II of protein Pb28 from Plasmodium berghei interacts with monoclonal transmission blocking antibody 13.1. J. Mol. Model 2009, 15(4):369-382. 10.1007/s00894-008-0404-y.
162. Shi Y.P., Alpers M.P., Povoa M.M., Lal A.A. Single amino acid variation in the ookinete vaccine antigen from field isolates of Plasmodium falciparum. Mol. Biochem. Parasitol. 1992, 50(1):179-180.
163. Shimp R.L., Rowe C., Reiter K., Chen B., Nguyen V., Aebig J., Narum D.L. Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle. Vaccine 2013, 31(28):2954-2962. 10.1016/j.vaccine.2013.04.034.
164. Sinden R.E. A biologist's perspective on malaria vaccine development. Hum. Vaccines 2010, 6(1):3-11.
165. Sinden R.E., Dawes E.J., Alavi Y., Waldock J., Finney O., Mendoza J., Basanez M.G. Progression of Plasmodium berghei through Anopheles stephensi is density-dependent. PLoS Pathog. 2007, 3(12):e195. 10.1371/journal.ppat.0030195.
166. Sinden R.E., Winger L., Carter E.H., Hartley R.H., Tirawanchai N., Davies C.S., Sluiters J.F. Ookinete antigens of Plasmodium berghei: a light and electron-microscope immunogold study of expression of the 21 kDa determinant recognized by a transmission-blocking antibody. Proc. R. Soc. Lond. B Biol. Sci. 1987, 230(1261):443-458.
167. Smith D.L., McKenzie F.E., Snow R.W., Hay S.I. Revisiting the basic reproductive number for malaria and its implications for malaria control. PLoS Biol. 2007, 5(3):e42. 10.1371/journal.pbio.0050042.
168. Smith T.A., Chitnis N., Briet O.J., Tanner M. Uses of mosquito-stage transmission-blocking vaccines against Plasmodium falciparum. Trends Parasitol. 2011, 27(5):190-196. 10.1016/j.pt.2010.12.011.
169. Srikrishnaraj K.A., Ramasamy R., Ramasamy M.S. Antibodies to Anopheles midgut reduce vector competence for Plasmodium vivax malaria. Med. Vet. Entomol. 1995, 9(4):353-357.
170. Stone W.J., Eldering M., van Gemert G.J., Lanke K.H., Grignard L., van de Vegte-Bolmer M.G., Bousema T. The relevance and applicability of oocyst prevalence as a read-out for mosquito feeding assays. Sci. Rep. 2013, 3:3418. 10.1038/srep03418.
171. Su X., Hayton K., Wellems T.E. Genetic linkage and association analyses for trait mapping in Plasmodium falciparum. Nat. Rev. Genet. 2007, 8(7):497-506. 10.1038/nrg2126.
172. Tachibana M., Sato C., Otsuki H., Sattabongkot J., Kaneko O., Torii M., Tsuboi T. Plasmodium vivax gametocyte protein Pvs230 is a transmission-blocking vaccine candidate. Vaccine 2012, 30(10):1807-1812. 10.1016/j.vaccine.2012.01.003.
173. Tachibana M., Wu Y., Iriko H., Muratova O., MacDonald N.J., Sattabongkot J., Tsuboi T. N-terminal prodomain of Pfs230 synthesized using a cell-free system is sufficient to induce complement-dependent malaria transmission-blocking activity. Clin. Vaccine Immunol. 2011, 18(8):1343-1350. 10.1128/CVI.05104-11.
174. Takeo S., Hisamori D., Matsuda S., Vinetz J., Sattabongkot J., Tsuboi T. Enzymatic characterization of the Plasmodium vivax chitinase, a potential malaria transmission-blocking target. Parasitol. Int. 2009, 58(3):243-248. 10.1016/j.parint.2009.05.002.
175. Talwar G.P., Singh O., Pal R., Chatterjee N., Sahai P., Dhall K., et al. A vaccine that prevents pregnancy in women. Proc. Natl. Acad. Sci. U.S.A. 1994, 91(18):8532-8536.
176. Templeton T.J., Kaslow D.C. Identification of additional members define a Plasmodium falciparum gene superfamily which includes Pfs48/45 and Pfs230. Mol. Biochem. Parasitol. 1999, 101(1-2):223-227.
177. Theisen M., Roeffen W., Singh S.K., Andersen G., Amoah L., van de Vegte-Bolmer M., Sauerwein R. A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stages. Vaccine 2014, 32(22):2623-2630. 10.1016/j.vaccine.2014.03.020.
178. Thiem V.D., Lin F.Y., Canh do G., Son N.H., Anh D.D., Mao N.D., Szu S.C. The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines. Clin. Vaccine Immunol. 2011, 18(5):730-735. 10.1128/CVI.00532-10.
179. Tine J.A., Lanar D.E., Smith D.M., Wellde B.T., Schultheiss P., Ware L.A., Paoletti E. NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Infect. Immun. 1996, 64(9):3833-3844.
180. Tomas A.M., Margos G., Dimopoulos G., van Lin L.H., de Koning-Ward T.F., Sinha R., Sinden R.E. P25 and P28 proteins of the malaria ookinete surface have multiple and partially redundant functions. EMBO J. 2001, 20(15):3975-3983. 10.1093/emboj/20.15.3975.
181. Toure Y.T., Doumbo O., Toure A., Bagayoko M., Diallo M., Dolo A., Kaslow D.C. Gametocyte infectivity by direct mosquito feeds in an area of seasonal malaria transmission: implications for Bancoumana, Mali as a transmission-blocking vaccine site. Am. J. Trop. Med. Hyg. 1998, 59(3):481-486.
182. Tsai C.W., Duggan P.F., Shimp R.L., Miller L.H., Narum D.L. Overproduction of Pichia pastoris or Plasmodium falciparum protein disulfide isomerase affects expression, folding and O-linked glycosylation of a malaria vaccine candidate expressed in P. pastoris. J. Biotechnol. 2006, 121(4):458-470. 10.1016/j.jbiotec.2005.08.025.
183. Tsai Y.L., Hayward R.E., Langer R.C., Fidock D.A., Vinetz J.M. Disruption of Plasmodium falciparum chitinase markedly impairs parasite invasion of mosquito midgut. Infect. Immun. 2001, 69(6):4048-4054. 10.1128/IAI.69.6.4048-4054.2001.
184. Tsuboi T., Kaneko O., Cao Y.M., Tachibana M., Yoshihiro Y., Nagao T., Torii M. A rapid genotyping method for the vivax malaria transmission-blocking vaccine candidates, Pvs25 and Pvs28. Parasitol. Int. 2004, 53(3):211-216.
185. Tsuboi T., Kaslow D.C., Gozar M.M., Tachibana M., Cao Y.M., Torii M. Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates. Mol. Med. 1998, 4(12):772-782.
186. Vaughan J.A., Noden B.H., Beier J.C. Population dynamics of Plasmodium falciparum sporogony in laboratory-infected Anopheles gambiae. J. Parasitol. 1992, 78(4):716-724.
187. Vermeulen A.N., Ponnudurai T., Beckers P.J., Verhave J.P., Smits M.A., Meuwissen J.H. Sequential expression of antigens on sexual stages of Plasmodium falciparum accessible to transmission-blocking antibodies in the mosquito. J. Exp. Med. 1985, 162(5):1460-1476.
188. Vermeulen A.N., Roeffen W.F., Henderik J.B., Ponnudurai T., Beckers P.J., Meuwissen J.H. Plasmodium falciparum transmission blocking monoclonal antibodies recognize monovalently expressed epitopes. Dev. Biol. Stand. 1985, 62:91-97.
189. Vermeulen A.N., van Deursen J., Brakenhoff R.H., Lensen T.H., Ponnudurai T., Meuwissen J.H. Characterization of Plasmodium falciparum sexual stage antigens and their biosynthesis in synchronised gametocyte cultures. Mol. Biochem. Parasitol. 1986, 20(2):155-163.
190. Vinetz J.M., Valenzuela J.G., Specht C.A., Aravind L., Langer R.C., Ribeiro J.M., Kaslow D.C. Chitinases of the avian malaria parasite Plasmodium gallinaceum, a class of enzymes necessary for parasite invasion of the mosquito midgut. J. Biol. Chem. 2000, 275(14):10331-10341.
191. Waye A., Jacobs P., Tan B. The impact of the universal infant varicella immunization strategy on Canadian varicella-related hospitalization rates. Vaccine 2013, 31(42):4744-4748. 10.1016/j.vaccine.2013.08.022.
192. Wenger E.A., Eckhoff P.A. A mathematical model of the impact of present and future malaria vaccines. Malar. J. 2013, 12:126. 10.1186/1475-2875-12-126.
193. Williams A.R., Zakutansky S.E., Miura K., Dicks M.D., Churcher T.S., Jewell K.E., Biswas S. Immunisation against a serine protease inhibitor reduces intensity of Plasmodium berghei infection in mosquitoes. Int. J. Parasitol. 2013, 43(11):869-874. 10.1016/j.ijpara.2013.06.004.
194. Williamson K.C., Criscio M.D., Kaslow D.C. Cloning and expression of the gene for Plasmodium falciparum transmission-blocking target antigen, Pfs230. Mol. Biochem. Parasitol. 1993, 58(2):355-358.
195. Williamson K.C., Fujioka H., Aikawa M., Kaslow D.C. Stage-specific processing of Pfs230, a Plasmodium falciparum transmission-blocking vaccine candidate. Mol. Biochem. Parasitol. 1996, 78(1-2):161-169.
196. Williamson K.C., Kaslow D.C. Strain polymorphism of Plasmodium falciparum transmission-blocking target antigen Pfs230. Mol. Biochem. Parasitol. 1993, 62(1):125-127.
197. Williamson K.C., Keister D.B., Muratova O., Kaslow D.C. Recombinant Pfs230, a Plasmodium falciparum gametocyte protein, induces antisera that reduce the infectivity of Plasmodium falciparum to mosquitoes. Mol. Biochem. Parasitol. 1995, 75(1):33-42.
198. Woo M.K., Kim K.A., Kim J., Oh J.S., Han E.T., An S.S., Lim C.S. Sequence polymorphisms in Pvs48/45 and Pvs47 gametocyte and gamete surface proteins in Plasmodium vivax isolated in Korea. Mem. Inst. Oswaldo Cruz 2013, 108(3). 10.1590/S0074-02762013000300015.
199. Wu Y., Craig A. Comparative proteomic analysis of metabolically labelled proteins from Plasmodium falciparum isolates with different adhesion properties. Malar. J. 2006, 5:67. 10.1186/1475-2875-5-67.
200. Wu Y., Ellis R.D., Shaffer D., Fontes E., Malkin E.M., Mahanty S., Durbin A.P. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One 2008, 3(7):e2636. 10.1371/journal.pone.0002636.
201. Wu Y., Przysiecki C., Flanagan E., Bello-Irizarry S.N., Ionescu R., Muratova O., Miller L.H. Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex. Proc. Natl. Acad. Sci. U.S.A. 2006, 103(48):18243-18248. 10.1073/pnas.0608545103.
202. Malaria Transmission Blocking Vaccines: An Ideal Public Good 2000, WHO Publication. http://www.who.int/tdr/publications/tdr-research-publications/malaria-transmission-blocking-vaccines/en/.
203. WHO Malaria Report 2014, http://www.who.int/malaria/publications/world_malaria_report_2014/report/en/.
204. Yuda M., Yano K., Tsuboi T., Torii M., Chinzei Y. von Willebrand Factor A domain-related protein, a novel microneme protein of the malaria ookinete highly conserved throughout Plasmodium parasites. Mol. Biochem. Parasitol. 2001, 116(1):65-72.
205. Zakeri S., Razavi S., Djadid N.D. Genetic diversity of transmission blocking vaccine candidate (Pvs25 and Pvs28) antigen in Plasmodium vivax clinical isolates from Iran. Acta Trop. 2009, 109(3):176-180. 10.1016/j.actatropica.2008.09.012.
206. Zieler H., Garon C.F., Fischer E.R., Shahabuddin M. A tubular network associated with the brush-border surface of the Aedes aegypti midgut: implications for pathogen transmission by mosquitoes. J. Exp. Biol. 2000, 203(Pt 10):1599-1611.
207. Zou L., Miles A.P., Wang J., Stowers A.W. Expression of malaria transmission-blocking vaccine antigen Pfs25 in Pichia pastoris for use in human clinical trials. Vaccine 2003, 21(15):1650-1657.